The global aneurysmal subarachnoid hemorrhage (SAH) treatment market is projected to experience significant growth in the coming years. This growth can be attributed to several factors, like a rising incidence of SAH globally, growing healthcare expenditure, and advancements in treatment modalities. The market is characterized by various factors,